Premium
Evaluation of body fat composition after linagliptin treatment in a rat model of diet‐induced obesity: a magnetic resonance spectroscopy study in comparison with sibutramine
Author(s) -
Klein T.,
Niessen H. G.,
Ittrich C.,
Mayoux E.,
Mueller H.P.,
Cheetham S.,
Stiller D.,
Kassubek J.,
Mark M.
Publication year - 2012
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/j.1463-1326.2012.01629.x
Subject(s) - sibutramine , linagliptin , endocrinology , obesity , medicine , appetite , type 2 diabetes , pharmacology , diabetes mellitus , weight loss
The effects of linagliptin on fat content in diet‐induced obese rats were compared with those of the appetite suppressant sibutramine. Female Wistar rats fed a high‐fat diet (HFD) for 3 months received vehicle, linagliptin (10 mg/kg) or sibutramine (5 mg/kg) treatment orally, once daily for 6 additional weeks, while continuing the HFD. Magnetic resonance spectroscopy analysis of fat content was performed at baseline and at the end of the 6‐week treatment period. Linagliptin treatment profoundly reduced hepatic fat compared with vehicle, with an effect comparable to that of sibutramine. The vehicle‐corrected mean change (95% CI) from baseline in hepatic fat and intramyocellular lipid was −59.0% (−104.3%, −13.6%; p = 0.015) and −62.1% (−131.6%, 7.4%; p = 0.073), respectively, for linagliptin compared with −54.3% (−101.5%, −7.1%; p = 0.027) and −72.4% (−142.4%, −2.4%; p = 0.044), respectively, for sibutramine.